ArticleFrontiers in cell and developmental biology2026
Danggui Shaoyao San ameliorates neuroinflammation in a D-galactose-induced Alzheimer's disease rat model by suppressing the JAK2/STAT3 pathway and modulating Th17/Treg -related immune dysregulation.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigates the therapeutic potential of Danggui Shaoyao San (DSS), a traditional Chinese herbal formula, focusing on its effects on Th17/Treg -associated immune regulation and the JAK2/STAT3 signaling pathway. Methods: Forty male Sprague-Dawley rats were randomly divided into five groups: control, AD model, low-dose DSS (12 g/kg/day, raw herbal materials), high-dose DSS (24 g/kg/day, raw herbal materials), and donepezil (0.5 mg/kg/day). AD models were established by intraperitoneal injection of D-galactose (100 mg/kg/day) for 8 consecutive weeks. Behavioral tests, flow cytometry, biochemical assays, histological analyses, qPCR, and Western blotting were used to evaluate DSS's effects. Untargeted metabolomics profiled metabolic alterations, while network pharmacology and molecular docking were integrated to predict key targets and pathways. Results: DSS treatment significantly alleviated neuronal damage, suppressed neuroinflammation, and improved learning and memory deficits in AD rats. Moreover, DSS was associated with alterations in Th17- and Treg-related immune dysregulation both in the brain and periphery. Serum metabolomic identified disruptions lipid metabolism and amino acid metabolism pathways. Network pharmacology and experimental validation indicated that DSS exerts its anti-neuroinflammatory effects by inhibiting JAK2 and STAT3 phosphorylation, reducing their nuclear translocation, and consequently suppressing Th17 differentiation and pro-inflammatory cytokine production. Conclusion: DSS is a promising candidate for AD treatment, with neuroprotective and cognitive-enhancing properties mediated through immunomodulation and JAK2/STAT3 pathway inhibition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.